Literature DB >> 8005575

Liver transplantation for hepatitis C virus-related cirrhosis.

N L Ascher1, J R Lake, J Emond, J Roberts.   

Abstract

Since the introduction of techniques to reliably identify antibody to the hepatitis C virus and quantitation of hepatitis C virus, there has been an increasing interest in the behavior of chronic hepatitis C infection with liver transplantation. Ninety-seven patients with chronic active hepatitis C and fifty-nine patients with cryptogenic cirrhosis underwent 100 and 62 liver transplantation procedures, respectively, at a single institution. This represents 35% of the total liver transplantations performed during this time period. Twenty-three percent of transplants were performed in patients with evidence of chronic active hepatitis C. Patients and graft survival were excellent in both groups. One-, 2- and 3-yr patient survival rates for chronic active hepatitis C and cryptogenic cirrhosis were 94%, 89% and 87% and 84%, 84% and 73%, respectively. Hepatitis C can frequently be identified after transplantation. More than 95% of patients show persistence of antibody to the hepatitis C virus. Forty-one of 95 patients (surviving > 1 mo) showed recurrent hepatitis (initially seen 3 to 20 mo after transplantation), and 12 progressed to chronic active hepatitis. In 16 patients of the cryptogenic group in whom hepatitis developed, 11 were associated with de novo hepatitis C infection. Seven of these 11 cases went on to a chronic state. Of 11 deaths after transplant in the hepatitis C group, 2 were directly related to recurrent disease. There were 15 deaths in the cryptogenic group, 2 related to de novo hepatitis C. Patients were not serotyped. Interferon therapy was attempted in a small number of patients with disease, with inconclusive results.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8005575     DOI: 10.1016/0270-9139(94)90269-0

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

Review 1.  Treatment of recurrent hepatitis C following liver transplantation.

Authors:  T Bizollon; C Ducerf; J Baulieux; C Trepo
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

2.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome.

Authors:  T Gayowski; N Singh; I R Marino; H Vargas; M Wagener; C Wannstedt; F Morelli; T Laskus; J J Fung; J Rakela; T E Starzl
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

4.  Liver transplantation in patients with chronic hepatitis C and alcoholism.

Authors:  S Dhar; L Omran; B R Bacon; H Solomon; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

5.  Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Authors:  Liesl M Hagan; Mark S Sulkowski; Raymond F Schinazi
Journal:  Hepatology       Date:  2014-05-14       Impact factor: 17.425

6.  Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Authors:  Phillip O Coffin; John D Scott; Matthew R Golden; Sean D Sullivan
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

7.  Treatment of chronic hepatitis C with amantadine.

Authors:  J P Smith
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

8.  Outcome of orthotopic liver transplantation in patients with hepatitis C.

Authors:  Seung W Paik; Henkie P Tan; Andrew S Klein; John K Boitnott; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

9.  Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Authors:  Sean D Sullivan; Antonio Craxi; Alfredo Alberti; Giovanni Giuliani; Claudio De Carli; Neil Wintfeld; Kavita K Patel; Jesse Green
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.